Skip to content

Vanda, BioDelivery Sciences, Zoetis new buys

May 26, 2017

Vanda Pharmaceuticals (NASDAQ:VNDA) initiated with Buy rating and $18 (29% upside) price target by H.C. Wainwright. Analyst cites “solid base business” with Fanapt and Hetlioz and “substantial upside” with pipeline.

BioDelivery Sciences (NASDAQ:BDSI) initiated with a Buy rating and $4 (82% upside) price target by H.C. Wainwright. Analyst cites “revitalized organization” with a “differentiated growth driver.”

Immunomedics (NASDAQ:IMMU) initiated with Outperform rating and $15 (101% upside) price target by Cowen and Company. Analyst cites compelling Phase 2 data for IMMU-132 for triple negative breast cancer that should make it the standard of care.

Zoetis (NYSE:ZTS) initiated with Buy rating and $71 (13% upside) price target by C.L. King.

http://bit.ly/2rorAx7

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: